ScreenerHero

KNSA Kiniksa Pharmaceuticals International, plc

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · kiniksa.com
77.09USD+1.02%Mkt Cap: 5.93B $P/E: 77.87

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interl…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.69BUSDP/E 25.5
TAK
Takeda Pharmaceutical Company Limited
$57.82BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.64BUSDP/E 65.2
HLN
Haleon plc
$39.01BUSDP/E 18.1
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.7
UTHR
United Therapeutics Corporation
$23.23BUSDP/E 19.4
VTRS
Viatris Inc.
$20.15BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.27BUSDP/E 111.6
NBIX
Neurocrine Biosciences, Inc.
$14.79BUSDP/E 21.3
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.23BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.40BUSDP/E 28.4
KRK
Krka, d. d.
$8.63BUSDP/E 19.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.07BUSDP/E 41.4
ALKS
Alkermes plc
$6.99BUSDP/E 109.6
HIMS
Hims & Hers Health, Inc.
$6.88BUSD
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 24.2
APTX
Apotex Health Corp.
$5.27BUSD
INDV
Indivior Pharmaceuticals, Inc.
$4.24BUSDP/E 12.9

Key Statistics

Company
Market Cap5.93B USD
Enterprise Value5.50B USD
Revenue (TTM)840.85M USD
Gross Profit370.35M USD
Net Income (TTM)59.01M USD
Revenue/Share11.03 USD
Last Price77.09 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees366
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)77.87
P/E (Forward)47.66
PEG—
EV/EBITDA53.88
EV/Revenue6.54
P/S7.05
P/B9.19
EPS (TTM)0.99
EPS (Forward)1.62
52W Range
35.2088% of range82.94
52W High82.94 USD
52W Low35.20 USD
Profitability
Gross Margin54.66%
Oper. Margin11.16%
EBITDA Margin12.14%
Profit Margin8.71%
ROE10.40%
ROA7.73%
Growth
Revenue Growth55.40%
Earnings Growth30.40%
Cash Flow & Leverage
Operating CF137.99M USD
CapEx (TTM)1.57M USD
FCF Margin15.00%
FCF Yield2.13%
Net Debt-517.03M USD
Net Debt/EBITDA-5.07
Balance Sheet
Debt/Equity0.02
Current Ratio3.90
Quick Ratio3.21
Book Value/Sh8.39 USD
Cash/Share6.74 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)98.00 USD
Upside (mean)+27.1%
Target Range87.00 USD – 108.00 USD
87.00+27.1% to mean108.00
# Analysts8
Ownership
Shares Out.46.30M
Float39.86M
Insiders3.51%
Institutions101.02%
Short Interest
Short Ratio7.9d
Short % Float9.70%
Short % Out.4.97%
Shares Short3.88M
Short (prev mo.)4.28M
Technical
SMA 5077.27 (-0.2%)
SMA 20056.39 (+36.7%)
Beta0.04
S&P 52W Chg15.78%
Avg Vol (30d)491.05K
Avg Vol (10d)537.56K
Technical Indicators
RSI (14)53.8
MACD0.0119
MACD Signal0.1783
MACD Hist.-0.1663
BB Upper78.69 USD
BB Middle76.44 USD
BB Lower74.19 USD
BB Width5.89%
ATR (14)2.588 USD
Vol Ratio (20d)0.74x